Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe oral and injectable forms of semaglutide for weight management are both licensed in the UK and work through the same GLP-1 receptor pathway, but their dosing schedules, practical routines and trial results differ in meaningful ways. The tablet (Wegovy, approved by the MHRA on 11 June 2026) reaches a 25mg daily maintenance dose; the injection (also Wegovy) reaches 2.4mg weekly, with a higher 7.2mg dose now also approved. Neither is a prescription you can obtain without a clinical assessment — a GPhC-registered prescriber reviews your suitability before any treatment is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A common assumption is that swallowing a pill must deliver less than an injection straight under the skin. The doses look wildly different (25mg by mouth against 2.4mg subcutaneously) so the gap seems to confirm it. In practice, oral semaglutide has very low gut absorption, which is why the tablet dose is so much higher; the delivered amount reaching your bloodstream is calibrated to produce a meaningful clinical effect. You can read more about how the tablet form works on our oral semaglutide overview page.
The OASIS 4 phase 3 trial (307 adults, 64 weeks, alongside lifestyle changes) recorded an average weight reduction of around 13.6% on the 25mg tablet versus roughly 2.4% on placebo. Among participants who stayed fully adherent, the average rose to approximately 16.6%. The injectable form's STEP 1 trial (68 weeks, 2.4mg) showed around 15% average reduction, as reported in the New England Journal of Medicine. Those figures are close enough that the choice between them is rarely settled by the headline number alone.
What changes more substantially is the practical experience: daily timing rules, fridge storage, needle technique. If you are unsure whether semaglutide comes as an oral tablet or an injection, our dedicated page explains exactly how each form is administered and why both routes exist. Our page on whether oral semaglutide matches the injection on effectiveness goes deeper into how those figures translate to real-world use.
The injection is taken once a week. The pen lives in the fridge door, retrieved briefly, brought to room temperature and administered at whatever day of the week you choose. Many people find a regular weekly slot (Sunday evening, say, or Monday morning) becomes habit quickly. Sharps disposal is a practical consideration worth planning for at the outset.
The tablet has a stricter daily ritual. It is taken first thing in the morning, on a completely empty stomach, with a small amount of plain water (up to around 120ml), and you wait at least 30 minutes before any food, coffee or other oral medicines. Miss that window and you will need to try again the next morning. No refrigeration is required, the tablet is room-temperature stable, which makes it more travel-friendly than the pen and suits people who find fridge management awkward.
For a fuller breakdown of day-to-day practicalities, the comparison on our semaglutide tablets vs injection page covers both forms side by side. If you are weighing the two forms specifically around whether tablets work as well, this page addresses that question directly.
Both forms carry a Black Triangle (▼) designation, meaning the MHRA monitors them with extra vigilance. Both are licensed for adults, not under-18s, and neither is recommended during pregnancy, while breastfeeding, or when trying to conceive.
The injection's licensed BMI thresholds are ≥30, or ≥27 with at least one weight-related condition. The tablet shares the same lower threshold (≥27 with a weight-related condition) but its ≥30 alone route is also available. Lower BMI thresholds apply for some ethnic backgrounds under NICE's appraisal of injectable semaglutide (TA875); the tablet's thresholds follow the MHRA licence rather than a NICE appraisal, as no appraisal existed at the time of writing. The MHRA's patient-level guidance on semaglutide is available on the NHS medicines pages and is worth reading alongside either form's Patient Information Leaflet.
The table below summarises the factual differences. Numbers are drawn from published trial data and MHRA licence documents.
| Factor | Wegovy injection (semaglutide) | Wegovy tablet (semaglutide) |
|---|---|---|
| Licensed in UK | Yes (weight management) | Yes, from 11 June 2026 (weight management) |
| Frequency | Once weekly | Once daily |
| Maintenance dose | 2.4mg (7.2mg also approved) | 25mg |
| Storage | Refrigerated (2–8°C) | Room temperature, no fridge needed |
| Average weight loss (trial) | ~15% at 68 weeks (STEP 1, NEJM) | ~13.6% at 64 weeks (OASIS 4); ~16.6% in fully adherent group |
| NHS availability | Via specialist services (NICE TA875) | Not yet appraised by NICE; private prescription only at launch |
Neither form has been declared superior for all patients, the evidence shows overlapping outcomes and different practical profiles. For anyone still deciding between the two options, our guide to semaglutide pills vs injection sets out the key considerations in one place to help you think it through before speaking to a prescriber. Which one fits your life, your medical history and your preferences is a clinical decision our prescribers make with you. You can explore both options on our treatment page, or read a broader overview of weight loss treatment approaches before starting a consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.